Anondita Medicare Ltd

About Anondita Medicare

Anondita Medicare manufactures condoms and family-planning products, including oral and emergency contraceptive pills, injectable contraceptives and IUCDs. Its portfolio also includes a pregnancy test kit under the COBRA Shubh Samachar brand, lubricants and female condoms. The company operates from Noida and supplies government tender programmes as well as retail, stockist and OEM channels. It has ISO 9001 and ISO 13485:2016 certifications and WHO GMP certification.

Investment Rationale

• Government procurement relationship: Anondita was awarded a CMSS tender in September 2025 as the lowest-cost qualified bidder. The single tender covers 257.5 Mn units across condoms, pregnancy kits, OCP, injectable contraceptives and IUCD.
• Revenue mix and channels: Condoms made up 99.8% of FY25 revenue. The government channel accounted for 57% of FY25 revenue, compared with 30% in FY23; Delhi and UP together accounted for ~98% of domestic sales.
• South African supply framework: The RT75-2025 framework covers condom and lubricant procurement for South African government healthcare facilities from 2025–2030. The factory audit and vendor qualification are complete, but formal purchase orders from South African local entities are awaited.
• Capacity additions: The report outlines an INR 75 Cr capex programme with a stated expansion capacity of 1,360 Mn pieces. It says 250 Mn pieces p.a. are under trial, with further phased capacity planned through Q4 FY27.
• Product and certification range: The company sells male condoms under COBRA and NIRODH, has relaunched the COBRA Shubh Samachar pregnancy test kit, and holds a patent for female condom manufacturing in India. The report highlights ISO 13485:2016, SABS, MDSAP, WHO GMP and BIS certifications in its institutional procurement discussion.

Business and Capacity

The company’s business is concentrated in condoms: the product-mix graphic shows condoms at 99.8% of FY25 sales. The report says glove and mask sales were discontinued after COVID. In FY25, the channel mix included government, subsidiary, stockists and OEM/others; exports were nil. The report presents the CMSS relationship as a recurring procurement opportunity, while retail under the COBRA brand is an additional route to market.

The report describes a phased capacity programme at a new unit in Sector 80, Noida, funded through debt and internal accruals. It cites operating leverage from existing fixed costs, but successful execution and utilisation depend on commissioning the planned capacity and securing demand.

Anondita Medicare Key Financials

The financial table shows rising revenue, EBITDA, PAT and EBITDA margin across the periods presented. The report also notes negative operating cash flow and working-capital stress.

Condom Market Outlook

The report presents the Indian condom market at USD 406.31 million in FY24 and USD 773.82 million in FY33, with a stated 7.45% CAGR. It says male condoms have over 95% share of the Indian market. Latex products accounted for 80.45% of 2024 revenue, while non-latex alternatives are expected to grow at a 10.56% CAGR.

For the global market, the report gives USD 11.9 billion for 2025 and USD 17.6 billion for 2032, with an 8.10% CAGR. It also highlights institutional procurement and donor distribution as significant volume channels.

Key Risks

• Cash flow and working capital: The report identifies negative cash flows and working-capital stress as high-severity risks. It separately highlights trade receivables of INR 48 cr against H1 revenue of INR 54 cr and negative OCF.
• Customer concentration: The top 10 customers account for 95%+ of revenue, according to the risk matrix.
• Tender dependence: Government contract dependency and debarment risk are listed as high severity.
• Manufacturing and product liability: The report flags reliance on a single Noida manufacturing facility and product-defect liability for contraceptives.
• Costs, distribution and debt: Other risks include centrifuged latex price volatility, reliance on third-party distributor Calcutta Cosmetics, secured and unsecured loan exposure, and interest-rate risk.

Our View

The report’s investment case centres on government procurement, the South African supply framework and planned capacity growth. The South African opportunity remains contingent on formal purchase orders, and the capacity build-out must be delivered while working-capital pressures are managed. The report does not state a share recommendation, target price or upside.

Standard disclosures

• Research Analyst has served as an officer, director or employee of subject company(ies): No
• We or our associates have received compensation from the subject company(ies) in the past 12 months: No
• We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
• We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months: No
• We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report: No
• We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies): No
• Nature of financial interest in subject company, if any: Nil
• We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of R: No
• Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report: No
• We or our Associates or Research Analyst are engaged in market making of subject company: No
• By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
• There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

Regulatory disclosures

• Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
• Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
• The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
• For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com | Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In | Equity Research Analyst for this report: Mr. Shubham Upadhyay (shubham.upadhyay@mcapital.in)